Pulmonx Corporation
Financials
Valuation Metrics
Pulmonx Corporation's Market Cap is $127M. At end of 2025 it was $92M. Ranked #3039 of 3,116 in US market (top 98%), #1404 of 1,472 on NASDAQ (top 95%), #195 of 203 in Health Care Equipment & Services (top 96%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $127M | US#3,039/3,116 Sec#195/203 |
| Revenue | $87M | US#2,693/3,116 Sec#187/203 |
| Net Income | $-48M | US—/3,116 Sec—/203 |
| Total Assets | $115M | US#3,045/3,116 Sec#199/203 |
| Net Assets | $39M | US#2,863/3,116 Sec#186/203 |
| Employees | 296 | US#2,409/3,116 Sec#166/203 |
| Value | ||
| P/B | 3.24x | US#1,888/3,116 Sec#103/203 |
| P/S | 1.45x | US#1,033/3,116 Sec#66/203 |
| FCF Yield | -24.16% | US—/3,116 Sec—/203 |
| Profitability | ||
| ROE | -122.76% | US#2,800/3,116 Sec#183/203 |
| ROA | -41.94% | US#2,950/3,116 Sec#196/203 |
| Op. Margin | -52.96% | US#2,658/3,116 Sec#182/203 |
| Revenue Growth | -3.43% | US#2,375/3,116 Sec#180/203 |
| Financial Health | ||
| Debt Ratio | 192.71% | US#1,745/3,116 Sec#150/203 |
| Total Debt | $56M | US#2,579/3,116 Sec#154/203 |
| FCF | $-31M | US#2,466/3,116 Sec#170/203 |
| Cash | $56M | US#2,537/3,116 Sec#161/203 |
| Current Ratio | 4.32x | US#535/3,116 Sec#50/203 |
| Performance | ||
| 1Y Return | 70.74% | US#355/3,116 Sec#38/203 |
| 1M Return | 57.33% | US#12/3,116 Sec#2/203 |
| From 52W High | -7.54% | US#265/3,116 Sec#34/203 |
| 1Y MDD | -55.00% | US#2,582/3,116 Sec#162/203 |
| Trading | ||
| Volume | 2,349,898 shares | US#358/3,116 Sec#18/203 |
| Trading Value | $7M | US#2,040/3,116 Sec#144/203 |
| Per Share | ||
| EPS | $-1.14 | US—/3,116 Sec—/203 |
| BPS | $0.93 | US#2,702/3,116 Sec#182/203 |
Company Info
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.